Chen Shu-Chih 4
4 · ATOSSA GENETICS INC · Filed May 31, 2018
Insider Transaction Report
Form 4
Chen Shu-Chih
DirectorChief Scientific Officer10% Owner
Transactions
- Purchase
Warrants
2018-05-30$1000.00/sh+2,272$2,272,000→ 2,272 total(indirect: See footnote)Exercise: $4.05From: 2018-05-30Exp: 2022-05-30→ Common Stock (2,272 underlying) - Purchase
Series B Convertible Preferred Stock
2018-05-30$1000.00/sh+8$8,000→ 8 total(indirect: See footnote)Exercise: $3.52From: 2018-05-30→ Common Stock (2,273 underlying)
Footnotes (5)
- [F1]Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52.
- [F2]Shares of Series B Convertible Preferred Stock do not expire.
- [F3]No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share.
- [F4]Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants.
- [F5]Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity.